| Literature DB >> 33568400 |
James M Turman1, Alana M Cheplowitz1, Charu Tiwari1, Thushara Thomas1, Dhruvi Joshi1, Menakshi Bhat2, Qian Wu3, Erik Pong4, Seung Y Chu4, David E Szymkowski4, Amit Sharma3,5, Stephanie Seveau3, John M Robinson6, Jesse J Kwiek2, Dennis Burton7, Murugesan V S Rajaram3, Jonghan Kim8, Lars Hangartner7, Latha P Ganesan9.
Abstract
Neutralizing Abs suppress HIV infection by accelerating viral clearance from blood circulation in addition to neutralization. The elimination mechanism is largely unknown. We determined that human liver sinusoidal endothelial cells (LSEC) express FcγRIIb as the lone Fcγ receptor, and using humanized FcγRIIb mouse, we found that Ab-opsonized HIV pseudoviruses were cleared considerably faster from circulation than HIV by LSEC FcγRIIb. Compared with humanized FcγRIIb-expressing mice, HIV clearance was significantly slower in FcγRIIb knockout mice. Interestingly, a pentamix of neutralizing Abs cleared HIV faster compared with hyperimmune anti-HIV Ig (HIVIG), although the HIV Ab/Ag ratio was higher in immune complexes made of HIVIG and HIV than pentamix and HIV. The effector mechanism of LSEC FcγRIIb was identified to be endocytosis. Once endocytosed, both Ab-opsonized HIV pseudoviruses and HIV localized to lysosomes. This suggests that clearance of HIV, endocytosis, and lysosomal trafficking within LSEC occur sequentially and that the clearance rate may influence downstream events. Most importantly, we have identified LSEC FcγRIIb-mediated endocytosis to be the Fc effector mechanism to eliminate cell-free HIV by Abs, which could inform development of HIV vaccine and Ab therapy.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33568400 PMCID: PMC7946731 DOI: 10.4049/jimmunol.2000772
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422